Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Sairah Ahmed, John F. DiPersio, James H Essell, Catherine S. Diefenbach, Miguel Angel Perales, Cristina Castilla-Llorente, Saurabh Dahiya, Sohail Chaudhry, Heng Xu, Yi Liu, Christie Fanton, Zachary Lee, Mario Q. Marcondes, Mary Tagliaferri, Jonathan Zalevsky, David B. Miklos, Cameron J. Turtle, Joseph P. McGuirk

Blood (2024) 144 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2024-203576

Published: 2024

Journal Articles

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Blood (2022) 140 (Supplement 1): 10357–10359.

https://doi.org/10.1182/blood-2022-162539

Published: 2022

Journal Articles

A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Miguel-Angel Perales, Sairah Ahmed, Saurabh Dahiya, Peter A. Riedell, Joseph P. McGuirk, Olalekan O. Oluwole, Sohail A. Chaudhry, Zachary Lee, Stanley Dai, Neha Dixit, Christie Fanton, Mario Q. Marcondes, Jonathan Zalevsky, Mary A. Tagliaferri, Cameron J. Turtle

Blood (2022) 140 (Supplement 1): 7488–7490.

https://doi.org/10.1182/blood-2022-162511

Published: 2022

Journal Articles

Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8 + T-Cells: Preliminary Results from a Phase 1 Study

Cameron J. Turtle, Elizabeth Budde, Krina K. Patel, Miguel-Angel Perales, Andrew J. Cowan, Hayder Saeed, Julio C. Chavez, Alexandre V. Hirayama, Delaney R. Kirchmeier, Murali Janakiram, Kai Wu, Lawrence Fong, Zachary Lee, Neha Dixit, Xiaoli Wang, Kazuharu Kai, Mario Q. Marcondes, Jonathan Zalevsky, Nina Shah

Blood (2021) 138 (Supplement 1): 2815.

https://doi.org/10.1182/blood-2021-147350

Published: 2021

Journal Articles

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Blood (2021) 138 (Supplement 1): 3134.

https://doi.org/10.1182/blood-2021-147758

Published: 2021

Journal Articles

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma

Nina D. Shah, MD, Cameron J. Turtle, MBBS, PhD, Andrew J. Cowan, MD, Julio C. Chavez, MD, Lihua E Budde, MD PhD, Mario Q. Marcondes, MD PhD, Zachary Lee, PharmD, Wei Lin, MD, Jonathan Zalevsky, Mary Tagliaferri, MD, Krina K. Patel, MDMSc

Blood (2019) 134 (Supplement_1): 4459.

https://doi.org/10.1182/blood-2019-122494

Published: 2019

Journal Articles

NKTR-255, a Polymer-Conjugated IL-15 Enhances Antibody-Dependent Cellular Cytotoxicity Mediated By NK Cells in a B Cell Lymphoma Model

Takahiro Miyazaki, Saul Kivimäe, Marlene Hennessy, Rhoneil Pena, Phi Quach, Andrew Moffet, Wildaliz Nieves, Ping Zhang, Mario Q. Marcondes, MD PhD, Loui Madakamutil, Jonathan Zalevsky

Blood (2019) 134 (Supplement_1): 5302.

https://doi.org/10.1182/blood-2019-127771

Published: 2019

Journal Articles

Pharmacokinetic and Pharmacodynamic Study of NKTR-255, a Polymer-Conjugated Human IL-15, in Cynomolgus Monkey

Takahiro Miyazaki, Peiwen Kuo, Mekhala Maiti, Palakshi Obalapur, Murali Addepalli, Werner Rubas, Paul Sims, Ping Zhang, Mario Q. Marcondes, MD PhD, Loui Madakamutil, Jonathan Zalevsky

Blood (2018) 132 (Supplement 1): 2952.

https://doi.org/10.1182/blood-2018-99-115638

Published: 2018

Journal Articles

The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates

Jonathan Zalevsky, Irene W. L. Leung, Sher Karki, Seung Y. Chu, Eugene A. Zhukovsky, John R. Desjarlais, David F. Carmichael, Chris E. Lawrence

Blood (2009) 113 (16): 3735–3743.

https://doi.org/10.1182/blood-2008-10-182048

Published: 2009

Journal Articles

Evaluation of the Pharmacokinetics, Immunogenicity, and Safety of XmAb®2513 in the Ongoing Study XmAb2513-01: A Phase 1 Study of Every Other Week XmAb2513 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients with Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

Anas Younes, MD, Jonathan Zalevsky, PhD, Kristie A. Blum, MD, Mitchell R Smith, MD, PhD, Henry C. Fung, MD, David A Ramies, MD, Chris E Lawrence, PhD, Daniel Combs, BS, Jeffrey Bloss, MD

Blood (2008) 112 (11): 5012.

https://doi.org/10.1182/blood.V112.11.5012.5012

Published: 2008

Journal Articles

XmAb®5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell Malignancies

Chris E Lawrence, PhD, Jonathan Zalevsky, PhD, Holly Horton, PhD, Irene Leung, PhD, Seung Chu, PhD, Sher Karki, PhD, Eugene Zhukovsky, PhD, John R Desjarlais, PhD, David F Carmichael, PhD

Blood (2008) 112 (11): 2621.

https://doi.org/10.1182/blood.V112.11.2621.2621

Published: 2008

Journal Articles

XmAb™2513, an Fc Engineered Humanized Anti-CD30 Monoclonal Antibody, Has Potent In Vitro and In Vivo Activities, and Has the Potential for Treating Hematologic Malignancies.

Chris E. Lawrence, PhD, Phil W. Hammond, PhD, Jonathan Zalevsky, PhD, Holly Horton, PhD, Seung Chu, PhD, Sher Karki, PhD, John R. Desjarlais, PhD, David F. Carmichael, PhD

Blood (2007) 110 (11): 2340.

https://doi.org/10.1182/blood.V110.11.2340.2340

Published: 2007

NARROW

NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8 + T-Cells: Preliminary Results from a Phase 1 Study

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma

NKTR-255, a Polymer-Conjugated IL-15 Enhances Antibody-Dependent Cellular Cytotoxicity Mediated By NK Cells in a B Cell Lymphoma Model

Pharmacokinetic and Pharmacodynamic Study of NKTR-255, a Polymer-Conjugated Human IL-15, in Cynomolgus Monkey

The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates

Evaluation of the Pharmacokinetics, Immunogenicity, and Safety of XmAb®2513 in the Ongoing Study XmAb2513-01: A Phase 1 Study of Every Other Week XmAb2513 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients with Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

XmAb®5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell Malignancies

XmAb™2513, an Fc Engineered Humanized Anti-CD30 Monoclonal Antibody, Has Potent In Vitro and In Vivo Activities, and Has the Potential for Treating Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only